5G phones cost a staggering $1,300. If you plan on buying one anytime soon… I got some news for you. It’s a worthless investment. 5G won’t work, unless this one tiny company steps in with its miraculous solution to save it. That’s according to E.B. Tucker. He’s a serial tech investor who made 13,000% in just 12 months — on one tech trade. E.B. believes the tiny company that’ll save 5G is the biggest stock market story for 2020. See full details here
Week of February 10, 2019
Markets are still mixed, despite strong economic news.
For example, job growth was explosive for January 2020 with 225,000 jobs added, as compared to expectations for an addition of 158,000.
The unemployment rate ticked higher, but that was because the labor participation rate climbed to 63.4%. Construction added 44,000 jobs. Manufacturing did see a loss of 12,000. Leisure and hospitality climbed by 36,000, as did healthcare. Professional and business services grew by 21,000, bringing to 390,000 the number of jobs the sector has added. Transportation and warehousing increased by 28,000.
Wages grew. Average hourly earnings rose 3.1% over a year ago to $28.44, says CNBC. “That marked 18 consecutive months of wage gains above 3%, as the initially reported 2.9% for December was revised up to 3%.”
As we wait to see what happens next in the markets, here’s what’s piquing our interest.
Opportunity No. 1
ATVI is gaining momentum on earnings, and as we near the release of new gaming consoles from Sony and Microsoft. The company just beat its own expectations with Q4 adjusted revenue of $2.71 billion. That was ahead of forecasts for $2.68 billion. In addition to the stock, the ATVI January 15, 2021 62.50 calls are also attractive, and offer us opportunity to profit from an expected bigger move on new console releases.
Opportunity No. 2
Aimmune Therapeutics Inc. (AIMT)
AIMT is a clinical-stage biopharmaceutical company that develops and commercializes product candidates for the treatment of peanut and other food allergies. The stock has been incredibly explosive, running from a low of $19 in July 2019 to a recent price of $29. 50.
However, we believe the stock could see higher highs after the U.S. FDA approved the company’s treatment for peanut allergies for those aged four through 17. The company also said this is just the beginning, as it waits for approval in Europe, and for trial results among children between the ages of one and four.
Opportunity No. 3
ZNGA also beat earnings expectations, with Wedbush analysts calling it a “near perfect” fourth quarter, as quoted by MarketWatch. Jefferies analysts also noted that, “despite increased investor caution heading into the print, Zynga posted impressive 4Q results and a safe [fiscal-year] guide that should help pull the stock out of the penalty box.”